NCT01361711View on ClinicalTrials.gov

Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

August 17, 2015

Study Completion Date

May 31, 2027

Conditions
Stage I Chronic Lymphocytic LeukemiaStage II Chronic Lymphocytic LeukemiaStage III Chronic Lymphocytic LeukemiaStage IV Chronic Lymphocytic Leukemia
Interventions
BIOLOGICAL

alemtuzumab

Given SC

BIOLOGICAL

ofatumumab

Given IV

PROCEDURE

biopsy

Correlative studies

Trial Locations (2)

60611

Northwestern University, Chicago

Unknown

Karolinska University Hospital Solna, Stockholm

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

collaborator

National Comprehensive Cancer Network

NETWORK

lead

Northwestern University

OTHER